TongliBio announces to complete pre-A round of financing by Tigermed investment group

Time：2020-04-29

4/29/2020. TongliBio announces to complete pre-A round of financing by Tigermed investment group. The fund will be used to advance clinical studies of lead candidate TL-010 and development of pipeline products.

Previous： TongliBio reaches a strategic partnership with Occam Biolabs, Inc.

Next： TongliBio announces to complete a clinical phase I trial with TL-010 in South Africa

Email：tl.office@tonglibio.com
Telephone：86-0512-58113269
Company Address：Rm 401, Bldg D, No.1 North Guotai Rd, Zhangjiagang, Suzhou, Jiangsu Province, PRC
苏ICP备13010604号

Name*

Email*

Tel*

Content

Submit

Technical support: Three to Five Interconnection

TOP